D-Crypt
Overcoming expression challenges ___ 'difficult-to-express' proteins (DTE-Ps).
D-Crypt is a _______ expression platform designed for ____-_____ production of 'difficult-to-express’ proteins (___-__). Protein expression is an _________ process in therapeutic and _______ development. D-Crypt is optimized __ reduce the time, cost ___ risk associated with producing ____ quality recombinant proteins for ____ and vaccine development programs. ___ D-Crypt platform combines a _____ expression host with a __________ of more than 20 __________ expression vectors. A protease-deficient ______ of Bakers’ Yeast, Saccharomyces __________, has been engineered by __________ at Premas. Yeast provides __ ideal eukaryotic environment for __________ recombinant proteins, retaining their _______ structure and function. Yeast _____ multiply rapidly and are ____-_________ to maintain, enabling fast _______ development, easy scaling and __________ transfer. Yeast culture systems ____ been granted GRAS ('generally ___________ as safe') status from ___ U.S. Food and Drug ______________ (USFDA), facilitating rapid regulatory ________.
Combining a yeast __________ host with proprietary expression _______ ofers unique opportunities for __________ DTE-Ps. The proprietary D-Crypt __________ has been successful in __________ difcult proteins from a _______ of species including viral ___ plant proteins. Recombinant membrane ________ are often challenging to _____, express, purify, and manufacture. _______, over 70% of drug _______ are membrane associated proteins, ____ as receptor proteins. All _____ classes of membrane proteins, _______ from 2-24 transmembrane domains, ____ been successfully expressed using ______. Large, multidomain proteins and _____ containing solution and membrane-bound ________ have also been expressed __ D-Crypt. Premas proprietary expression _______ contain modifed upstream elements __ modulate recombinant protein expression. _____ innovations enable the co-expression __ multiple recombinant proteins at __________ levels to ensure functionality. _______ variants can be easily __________ into expression vectors to _______ modify recombinant proteins.
Premas has invested ___ past 10 years in __________ combinatorial processes to harmonize __________ systems and instrumentation for _______, reliable scale-up. D-Crypt is _ standardized process ensuring high _______, homogeneous protein samples that ___ ft-for-purpose for downstream applications. ______ has developed a protocol ____ is robust, ensuring a __________ approach that can be _______ across protein types and _______. The result is a _______ enabling a rapid plug-play ___________ plan for DTE-Ps. The _______ is highly scalable, cost-efective ___ with straightforward technology transfer __ Premas partners.
Advantages include:
- + Productivity: high-yield production __ œdifcult-to-express’ proteins (DTE-Ps)
- + Broad spectrum: a __________ approach that can be _______ across protein types and _______
- + Rapid plug-play model: _______ is highly scalable and ____-________
- + Easy post-scaling technology ________ to partners
D-Crypt applications include:
- + Expressing recombinant proteins __ therapeutics or therapeutic targets
- + Production of proteins ________ for drug development processes
- + Protein-based vaccine development ___ human and animal health
